Trials
Search / Trial NCT00000371

Trial of D-Cycloserine in Schizophrenia

Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 2, 1999

Apply for Trial

Trial Information

Current as of January 15, 2025

Completed

Keywords

Adult Cognition Cycloserine Dopamine Female Glutamic Acid Human Male Receptors, N Methyl D Aspartate Schizophrenia Serotonin Quality Of Life Cycloserine *Therapeutic Use Dopamine Blood Dopamine Cerebrospinal Fluid Glutamic Acid Blood Glutamic Acid Cerebrospinal Fluid Serotonin Blood Serotonin Cerebrospinal Fluid

ClinConnect Summary

To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic, and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response.

Dysfunction of glutamatergic neuronal systems has recently been implicated in...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Diagnosis of Schizophrenia as per DSM IV criteria
  • • Have been treated for at least 6 months with any conventional neuroleptic
  • • Have prominent negative symptoms as defined by a total score of 40 or greater on the scale for the assessment of negative symptoms (SANS)
  • Exclusion Criteria:
  • • Active alcohol or drug abuse
  • • Unstable Medical Illness, seizure disorder, or other serious neurological disorder
  • • Pregnant or Nursing
  • • Unable to complete a cognitive battery

Trial Officials

Donald Goff, MD

Principal Investigator

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials